AML in Adults

Jurjen Versluis; Jan J. Cornelissen; Charles Craddock; Miguel Sanz; Arnon Nagler

doi:10.1007/978-3-031-44080-9_70

AML in Adults

Jurjen Versluis^*
, Jan J. Cornelissen
, Charles Craddock
, Miguel Sanz
, Arnon Nagler

^*Corresponding author for this work

Hematology

University Hospitals Birmingham NHS Foundation Trust
University of Warwick
University of Valencia
Centro de Investigación Biomédica en Red (CIBER)
Sheba Medical Center at Tel Hashomer

Research output: Chapter/Conference proceeding › Chapter › Academic

1 Citation (Scopus)

23 Downloads (Pure)

Abstract

AML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts. AML is increasingly being recognized as a heterogenous malignancy based on distinct disease biology and underlying cytogenetic and molecular profiles. These profiles and measurable residual disease after induction therapy direct post-remission strategies in a risk-adapated approach, which also includes the assessment of the risk of treatment-related mortality. In primary refractory AML, allo-HSCT remains a curative treatment option in fit patients. Allo-HSCT in acute promyelocytic leukemia is only recommended for specific cases, particularly when not in moleculair remission after treatment for first relapse.

Original language	English
Title of host publication	The EBMT Handbook
Subtitle of host publication	Hematopoietic Cell Transplantation and Cellular Therapies
Editors	Anna Sureda, Selim Corbacioglu, Raffaella Greco, Nicolaus Kröger, Enric Carreras
Publisher	Springer International Publishing
Pages	617-631
Number of pages	15
Edition	8
ISBN (Electronic)	9783031440809
ISBN (Print)	9783031440793
DOIs	https://doi.org/10.1007/978-3-031-44080-9_70
Publication status	Published - Apr 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Access to Document

10.1007/978-3-031-44080-9_70Licence: CC BY

978-3-031-44080-9_70Final published version, 631 KBLicence: CC BY

Cite this

@inbook{84baf8393e0f4f0b9266e9c755fbca19,

title = "AML in Adults",

abstract = "AML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts. AML is increasingly being recognized as a heterogenous malignancy based on distinct disease biology and underlying cytogenetic and molecular profiles. These profiles and measurable residual disease after induction therapy direct post-remission strategies in a risk-adapated approach, which also includes the assessment of the risk of treatment-related mortality. In primary refractory AML, allo-HSCT remains a curative treatment option in fit patients. Allo-HSCT in acute promyelocytic leukemia is only recommended for specific cases, particularly when not in moleculair remission after treatment for first relapse.",

author = "Jurjen Versluis and Cornelissen, \{Jan J.\} and Charles Craddock and Miguel Sanz and Arnon Nagler",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = apr,

doi = "10.1007/978-3-031-44080-9\_70",

language = "English",

isbn = "9783031440793",

pages = "617--631",

editor = "\{Anna Sureda, Selim Corbacioglu, Raffaella Greco, Nicolaus Kr{\"o}ger, Enric Carreras\}",

booktitle = "The EBMT Handbook",

publisher = "Springer International Publishing",

address = "Switzerland",

edition = "8",

}

AML in Adults. / Versluis, Jurjen; Cornelissen, Jan J.; Craddock, Charles et al.
The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. ed. / Anna Sureda, Selim Corbacioglu, Raffaella Greco, Nicolaus Kröger, Enric Carreras. 8. ed. Springer International Publishing, 2024. p. 617-631.

Research output: Chapter/Conference proceeding › Chapter › Academic

TY - CHAP

T1 - AML in Adults

AU - Versluis, Jurjen

AU - Cornelissen, Jan J.

AU - Craddock, Charles

AU - Sanz, Miguel

AU - Nagler, Arnon

PY - 2024/4

Y1 - 2024/4

N2 - AML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts. AML is increasingly being recognized as a heterogenous malignancy based on distinct disease biology and underlying cytogenetic and molecular profiles. These profiles and measurable residual disease after induction therapy direct post-remission strategies in a risk-adapated approach, which also includes the assessment of the risk of treatment-related mortality. In primary refractory AML, allo-HSCT remains a curative treatment option in fit patients. Allo-HSCT in acute promyelocytic leukemia is only recommended for specific cases, particularly when not in moleculair remission after treatment for first relapse.

AB - AML is a malignancy of hematopoietic immature precursors (myeloblasts) that accumulate in the BM at the expense of their normal counterparts. AML is increasingly being recognized as a heterogenous malignancy based on distinct disease biology and underlying cytogenetic and molecular profiles. These profiles and measurable residual disease after induction therapy direct post-remission strategies in a risk-adapated approach, which also includes the assessment of the risk of treatment-related mortality. In primary refractory AML, allo-HSCT remains a curative treatment option in fit patients. Allo-HSCT in acute promyelocytic leukemia is only recommended for specific cases, particularly when not in moleculair remission after treatment for first relapse.

UR - https://www.scopus.com/pages/publications/85207223612

U2 - 10.1007/978-3-031-44080-9_70

DO - 10.1007/978-3-031-44080-9_70

M3 - Chapter

AN - SCOPUS:85207223612

SN - 9783031440793

SP - 617

EP - 631

BT - The EBMT Handbook

A2 - , Anna Sureda, Selim Corbacioglu, Raffaella Greco, Nicolaus Kröger, Enric Carreras

PB - Springer International Publishing

ER -

AML in Adults

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this